Trasylol Label Should Get Warning, But Not Study Details Advisory Cmte. Says
Executive Summary
Following a Sept. 12 advisory committee meeting evaluating safety signals for Bayer's Trasylol (aprotinin), FDA faces the question of how to re-label a drug with uncertain but serious risks